Myriad Genetics 2025 Q2 Earnings Deepening Losses Amid Raised Revenue Guidance

Myriad Genetics reported mixed second-quarter results, with revenue rising slightly year-over-year but a significant net loss widening. The company raised its full-year revenue guidance to $818–$828 million from $807–$823 million, reflecting improved business performance and updated market expectations, while reiterating its adjusted EPS range of $(0.02)–$0.02.

Revenue
Total revenue increased by 0.8% year-over-year to $213.10 million, with hereditary cancer and prenatal segments showing notable growth. Hereditary cancer revenue reached $96.30 million, reflecting a 5% increase, while prenatal revenue climbed 7% to $47.60 million. Tumor profiling revenue declined by 4% to $31.40 million, primarily due to the sale of the international EndoPredict business. Pharmacogenomics revenue fell 12% to $37.80 million, impacted by UnitedHealthcare’s decision to discontinue coverage for certain tests.

Earnings/Net Income
The company reported a net loss of $330.50 million in Q2 2025, representing a 800.5% increase from the $36.70 million loss in Q2 2024. Earnings per share (EPS) were $(3.57), a 770.7% wider loss compared to $(0.41) in the prior year. The loss was driven largely by non-cash impairment charges of $316.70 million, primarily due to a decline in market capitalization.

Price Action
The stock price of Myriad Genetics has experienced a significant decline in recent trading periods. During the latest trading day, shares fell 2.76%, while the full week showed a 5.61% drop. Over the past month, the stock has plummeted 30.89%, indicating a challenging near-term performance for investors.

Post Earnings Price Action Review
A strategy of purchasing Myriad Genetics shares following a revenue increase quarter-over-quarter and holding for 30 days has performed poorly over the past three years. This approach led to a -77.99% return, significantly underperforming the benchmark’s 48.58%. The strategy showed no volatility, with a maximum drawdown of 0.00%, yet its Sharpe ratio of -0.68 highlighted the negative risk-adjusted return. The lack of volatility did not compensate for the substantial loss in value, reinforcing the strategy’s poor performance.

CEO Commentary
Sam Raha, President and CEO, emphasized a “solid Q2 2025 performance,” highlighting growth in hereditary cancer testing, favorable pricing trends, and disciplined expense management. He outlined a renewed focus on the Cancer Care Continuum (CCC), including therapy selection, immuno-oncology, and Molecular Residual Disease (MRD). The CEO noted plans for an early 2026 launch of a proprietary MRD test and a partnership with OrbiMed to support long-term goals. Raha expressed confidence in the company’s updated strategy and its ability to create sustained value.

Guidance
Myriad Genetics raised its full-year 2025 revenue guidance to a range of $818–$828 million, citing Q2 results, the new credit facility, and the current business outlook. The company reiterated its adjusted EPS range of $(0.02)–$0.02 for 2025. It aims to grow revenue at or above market in the Prenatal and Mental Health segments, maintain high single-digit to low double-digit revenue growth over five years, and prioritize profitability through disciplined expense management, stable pricing, and operational efficiency.

Additional News
On July 31, 2025, Myriad Genetics secured a new $200 million credit facility to enhance financial flexibility and support its growth strategy. The company also announced plans to launch a proprietary Molecular Residual Disease (MRD) test by early 2026 as part of its expanded focus on the Cancer Care Continuum. In the Women’s Health segment, prenatal testing revenue grew 7% year-over-year, driven by increased payer coverage for Foresight Expanded Carrier Screen. Meanwhile, the company’s partnership with PATHOMIQ aims to introduce its first AI-driven prostate cancer test in early 2026. Despite these strategic advancements, the company faced challenges in the pharmacogenomics segment due to UnitedHealthcare’s coverage decision and the divestiture of its European EndoPredict business. Myriad remains committed to its long-term goals, emphasizing disciplined financial management and innovation to drive sustainable value.